Published in Nat Med on June 01, 2003
Angiogenesis Inhibitors and Hypertension: Clinical Aspects | NCT00511511
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 4.91
Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature (2010) 4.78
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol (2004) 4.47
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol (2008) 4.43
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42
Heart valve development: endothelial cell signaling and differentiation. Circ Res (2004) 4.41
MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One (2006) 4.29
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol (2005) 4.03
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med (2005) 3.98
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 3.93
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Narrative review: the systemic capillary leak syndrome. Ann Intern Med (2010) 3.71
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology (2009) 3.68
Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell (2008) 3.56
Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer (2010) 3.48
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol (2004) 3.47
A mechanosensitive transcriptional mechanism that controls angiogenesis. Nature (2009) 3.44
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Molecular pathology of age-related macular degeneration. Prog Retin Eye Res (2008) 3.35
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood (2005) 2.91
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc Natl Acad Sci U S A (2006) 2.89
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 2.77
Vascular endothelial growth factor in eye disease. Prog Retin Eye Res (2008) 2.73
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68
Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med (2006) 2.63
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol (2010) 2.52
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A (2009) 2.41
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A (2005) 2.38
The effect of matrix density on the regulation of 3-D capillary morphogenesis. Biophys J (2007) 2.37
Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med (2007) 2.37
The axonal attractant Netrin-1 is an angiogenic factor. Proc Natl Acad Sci U S A (2004) 2.34
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A (2007) 2.22
Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis. Nat Cell Biol (2014) 2.22
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med (2012) 2.21
NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer (2009) 2.18
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med (2006) 2.16
Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest (2005) 2.11
The theory of facilitated variation. Proc Natl Acad Sci U S A (2007) 2.10
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev (2012) 2.10
HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol (2011) 2.10
Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med (2005) 2.10
alphaB-crystallin regulation of angiogenesis by modulation of VEGF. Blood (2009) 2.10
Fluid forces control endothelial sprouting. Proc Natl Acad Sci U S A (2011) 2.09
Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. Nat Chem Biol (2006) 2.08
Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res (2006) 2.08
Tissue remodelling through branching morphogenesis. Nat Rev Mol Cell Biol (2009) 2.06
Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest (2004) 2.03
Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol (2015) 2.03
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol (2007) 1.99
Vascular endothelial-cadherin regulates cytoskeletal tension, cell spreading, and focal adhesions by stimulating RhoA. Mol Biol Cell (2004) 1.98
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
Cancer as a metabolic disease. Nutr Metab (Lond) (2010) 1.98
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 1.98
A direct and melanopsin-dependent fetal light response regulates mouse eye development. Nature (2013) 1.98
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96
Material-based deployment enhances efficacy of endothelial progenitor cells. Proc Natl Acad Sci U S A (2008) 1.96
Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry (2006) 1.96
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist (2012) 1.96
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 1.95
Hif-1alpha regulates differentiation of limb bud mesenchyme and joint development. J Cell Biol (2007) 1.95
CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem (2008) 1.93
Human studies of angiogenic gene therapy. Circ Res (2009) 1.92
Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J Cell Biol (2010) 1.92
Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol (2007) 1.88
VEGF-induced vascular permeability is mediated by FAK. Dev Cell (2012) 1.85
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther (2008) 1.84
PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev (2008) 1.80
Cross-kingdom comparison of transcriptomic adjustments to low-oxygen stress highlights conserved and plant-specific responses. Plant Physiol (2010) 1.79
Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J Biol Chem (2008) 1.78
A sex-specific role for androgens in angiogenesis. J Exp Med (2010) 1.78
VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood (2007) 1.78
The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation. PLoS One (2008) 1.78
VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis. Arterioscler Thromb Vasc Biol (2008) 1.77
Vascular endothelial growth factor-A specifies formation of native collaterals and regulates collateral growth in ischemia. Circ Res (2008) 1.77
VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2. Exp Cell Res (2007) 1.76
Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76
State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. Proc Am Thorac Soc (2006) 1.75
A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. Biophys J (2007) 1.74
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol (2007) 1.73
Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J (2008) 1.72
Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci U S A (2007) 1.71
The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J Biol Chem (2004) 1.69
RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J (2010) 1.67
FGF9 and SHH regulate mesenchymal Vegfa expression and development of the pulmonary capillary network. Development (2007) 1.67
Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest (2004) 1.67
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci U S A (2007) 1.66
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst (2007) 3.95
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell (2006) 3.10
Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin. FASEB J (2007) 2.30
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem (2002) 2.02
Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development (2005) 1.93
Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell (2012) 1.79
A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A (2014) 1.77
Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci (2008) 1.63
Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood (2004) 1.62
Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost (2004) 1.55
Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Dev Biol (2007) 1.51
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol (2008) 1.40
Rat-to-elephant-to-human transmission of cowpox virus. Emerg Infect Dis (2008) 1.40
Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. Physiol Genomics (2004) 1.40
Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol (2003) 1.37
Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res (2006) 1.29
Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol (2014) 1.20
Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells. J Biol Chem (2001) 1.20
The forming limb skeleton serves as a signaling center for limb vasculature patterning via regulation of Vegf. Development (2009) 1.16
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res (2008) 1.11
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood (2007) 1.09
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther (2012) 1.01
Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs (2011) 0.99
EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors. Biochim Biophys Acta (2004) 0.99
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther (2008) 0.99
Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol (2012) 0.98
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs (2009) 0.97
Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther (2008) 0.95
Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis. J Immunol (2009) 0.89
Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood (2005) 0.88
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn (2013) 0.86
CD40 expression on antigen presenting cells and correlation with disease severity in atopic dermatitis. Eur J Dermatol (2008) 0.85
The function of VEGF-A in lens development: formation of the hyaloid capillary network and protection against transient nuclear cataracts. Exp Eye Res (2008) 0.84
CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity. Eur J Dermatol (2007) 0.82
Endocrine gland vascular endothelial growth factor (EG-VEGF) and the hypothesis of tissue-specific regulation of angiogenesis. Endocr Res (2002) 0.79
Americas Antibody Congress: September 21-23, 2009, Washington, D.C. MAbs (2009) 0.75